operational efficiency Archives - Medical Design Sourcing

Commitment to operational efficiency and partnerships yield dividends for Teva

Teva’s strategy to boost its operational efficiency and tap strategic partnerships seems to be paying off. In its Q3 earnings report, Teva announced that global revenues were up to $3.9 billion, marking a 7% rise from the previous year’s third quarter. Factors fueling the growth include the robust performance of their specialty medications, Austedo and Ajovy, as well as a strong showing from their generics portfolio. However, despite these promising stats, investors appear to be cautious. Teva’s stock is down almost 8% so far this year, currently trading at $8.77.

For Austedo, Sven Dethlefs, the company’s head of North America commercial, noted that the company has seen growth for the extended-release version of the drug. In an earnings call, Dethlefs said the company has seen “a significant number of new prescribers that have never prescribed Austedo before that now start prescribing Austedo XR.” He added that the demand for the …

Discover new levels of efficiency in pharma manufacturing with advanced analytics

[max_776/Adobe Stock]

Digitalization empowers pharmaceutical companies to bring therapies to patients faster by using advanced analytics strategies to profitably optimize manufacturing operations.

In the pharmaceutical industry, operational issues from efficiency losses to failed batches can delay delivery of potentially lifesaving therapies to patients. For this and other reasons, pharmaceutical organizations require resources dedicated to batch prediction, planning and rapid issue resolution throughout the entirety of a drug’s lifecycle. Because the field is both highly regulated and consequential, decisions must be data-based to ensure compliance and product integrity.

Adding to the challenge, patient populations are ever-evolving and conditions in the supply chain are variable. At the same time, there is growing pressure to lower the cost of bringing drugs to market, without compromising safety and…

McKinsey has a digital prescription for pharma processing

Digital plant maturity model. Image courtesy of Emerson.

Given the recent surge in interest in generative AI, it’s no wonder that consultancies like McKinsey are making hay of the situation. The consultancy recently argued that “Rewired pharma companies will win in the digital age.” In a separate feature, it noted that generative AI could boost biopharma R&D productivity by billions, as we reported on Drug Discovery & Development.

It is true that the pharma sector faces significant headwinds as digital and analytical capabilities reshape healthcare. To keep up with this rapid pace of change, McKinsey argues that pharma companies must tap digital technologies to improve patient outcomes, increase efficiency and drive growth. Many firms are hiring chief digital and technology officers, it noted, but digital adoption in pharma generally remains at an early phase.

Building a solid d…

The need for a data-driven culture in life sciences: What you don’t know can hurt you

Preventing sudden failures and unexpected downtime in life sciences organizations starts with promoting a data-driven culture across the enterprise.

[Image courtesy of Oleksii/Adobe Stock]

Promoting a data-driven culture across the enterprise is what makes today’s most successful life sciences organizations stand out. Efficient operations are only possible when the processes underlying those activities are functional, and this type of reliable operation depends on acute visibility. That visibility is, in turn, reliant on clear, comprehensive maintenance and equipment reliability data. When equipment is down due to an unexpected failure, processes grind to a halt and costs skyrocket.

For this reason, today’s most successful life sciences organizations are expanding their focus as they now place the same value on their maintenance and reliability data as their operational data. These teams are bui…